News | August 16, 2022
ResMed Q4 revenue up 4%; operating profit up 6%
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
Subscribe To Our Newsletter & Stay Updated
